# Pluri Biotech Ltd.

Canonical: https://abierto.us/vendors/pluri-biotech-ltd-medcue4lmze6

- UEI: MEDCUE4LMZE6
- CAGE: 3704A
- Parent: Pluristem Therapeutics Inc.
- Location: Haifa, ISR
- Awards in window: 1 (2 transactions), $1,416,470 obligated, June 3, 2024 to April 15, 2025

## Awarding agencies

- National Institutes of Health: 1 awards, $1,416,470

## Industries

- 541714 Research and Development in Biotechnology (except Nanobiotechnology): $1,416,470

## Competition

- Full and Open Competition: 1 awards

## Largest awards

- 75N93023C00012 (definitive contract): $1,416,470, National Institutes of Health Niaid. Development of Plx-R18 Cell Therapy as a Countermeasure for Hematopoietic Acute Radiation Syndrome. https://www.usaspending.gov/award/CONT_AWD_75N93023C00012_7529_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/pluri-biotech-ltd-medcue4lmze6.